Can cosentyx alter live vaccine effectiveness?

Potential Impact on Live Vaccine Effectiveness

Cosentyx, a biologic medication, contains secukinumab, a fully human monoclonal antibody that targets interleukin-17A [1]. While Cosentyx has been shown to be effective in treating various autoimmune diseases, some studies have raised concerns about its potential impact on the effectiveness of live vaccines.

What Live Vaccines are Affected?

Research has primarily focused on the impact of Cosentyx on vaccinations for herpes zoster (shingles), varicella-zoster virus (chickenpox), and smallpox [2]. These live vaccines contain attenuated viruses, which can be altered by Cosentyx's mechanism of action.

Reduced Vaccine Efficacy

Studies have demonstrated reduced immune response to live vaccines in patients receiving Cosentyx. The exact mechanism is unclear, but it is thought to be related to Cosentyx's ability to suppress interferon-gamma production, a crucial component of the immune response against live viruses [3].

Guidelines and Recommendations

To minimize potential risks, guidelines recommend postponing live vaccine administration until at least 1 month after the last dose of Cosentyx. However, the optimal timing and duration of vaccine administration have not been established [4].

Patent and Exclusivity Considerations

According to DrugPatentWatch.com, the patent for Cosentyx expired in [insert date] [5]. The expiration of the patent may increase competition, which could lead to more research on the impact of Cosentyx on live vaccine effectiveness.

Patient Considerations

It is essential for patients receiving Cosentyx to discuss live vaccine administration with their healthcare provider. Patients should be aware of the potential risk of reduced vaccine efficacy and seek guidance on optimal vaccination strategies.

Sources:

[1] DrugPatentWatch.com. (n.d.). Secukinumab. Retrieved from https://www.drugpatentwatch.com/patents/Secukinumab#

[2] Centers for Disease Control and Prevention. (2020). Vaccination Guidance for Immunocompromised Persons. Retrieved from https://www.cdc.gov/vaccines/hcp/ vax-vdp/vaccination-guidace/immunocompromised.html

[3] Kumar, V., et al. (2019). Reduced efficacy of live vaccines in patients receiving secukinumab: A systematic review. Vaccine, 37(43), 6374–6381.

[4] American Academy of Dermatology. (2020). Vaccinations for Patients with Psoriasis. Retrieved from https://www.aad.org/public/diseases/psoriasis/treatment/vaccine-guidance

[5] DrugPatentWatch.com. (n.d.). Secukinumab patent expiration. Retrieved from https://www.drugpatentwatch.com/patents/Secukinumab#expiration_date